Author

R. E. Davis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Berkova· 1 shared A. D. D'Andrea· 1 shared A. Dolnikova· 1 shared A. Farkkila· 1 shared A. Haouz· 1 shared A. Li· 1 shared A. Mechaly· 1 shared A. Rajmonova· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Berkova

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies

N. Bettazova, J. Senavova, K. Kupcova, D. Sovilj, A. Rajmonova, L. Andera, K. Svobodova, A. Berkova, V. Herman, Z. Zemanova, L. Daumova, A. Dolnikova, R. E. Davis, M. Trneny, P. Klener, O. Havranek

This study investigates how PIK3CA gain and PTEN loss affect MCL biology and drug response, finding reduced BCR dependence and increased therapy resistance.

bioRxiv · Apr 30, 2024Cancer Biology

CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy

H. Yang, W. Zhang, V. Ravanmehr, A. Mechaly, L. Regad, A. Haouz, R. Chen, J. Henderson, E. Rojas, A. Wilson, S. Parsons, L. Nastoupil, R. E. Davis, Q. Deng, F. Samaniego, , M. R. Green

The paper shows that CREBBP mutations disrupt chromatin loading dynamics and EP300 redundancy, creating zombie enzymes that impair enhancer activation in GC B-cells and lymphoma.

bioRxiv · Sep 5, 2023 · PreprintCancer Biology

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

J. Zhou, C. Gelot, C. Pantelidou, A. Li, H. Yucel, R. E. Davis, A. Farkkila, B. Kochupurakkal, A. Syed, G. I. Shapiro, J. A. Tainer, B. S. Blagg, R. Ceccaldi, A. D. D'Andrea

The paper identifies Novobiocin as a POLθ inhibitor that selectively kills HR-deficient tumors, including those resistant to PARP inhibitors.

bioRxiv · May 23, 2020Cancer Biology